The IMF is aware that shortages of many medications are affecting patients throughout the United States. We are particularly concerned that patients currently being treated with DOXIL (which is approved in combination with VELCADE) are unable to receive this drug. Our advocacy team is actively involved in promoting passage of the Preserving Access to Life-Saving Medications Act (S. 296 and H.R. 2245), which would give the Food and Drug Administration (FDA) the ability to require advance notification from drug manufacturers about factors that could lead to drug shortages.
Further information about this IMF advocacy effort is available on our web site at the IMF Advocacy Action Center.
There is currently a waiting list for DOXIL that is available to prescribing physicians. If you are a myeloma patient who has not been able to get DOXIL, please call the IMF Hotline at 800-452-2873 to share your story and get further information.